Aelis Farma SA (AELIS.PA)
Paris · EUR · Healthcare · Biotechnology
€0.649 (-1.67%) as of
Key statistics
- Market cap
- 8.85M
- Forward P/E
- 3.82
- EPS (TTM)
- -0.3300
- Dividend yield
- 0.00%
- 52-week range
- 0.6100 – 2.3000
- Beta
- 0.64
- Revenue (TTM)
- 2.19M
- Profit margin
- -216.29%
- Volume
- 5.40k
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Bordeaux, France
- Employees
- 14
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.